Home » MEETING COVERAGE » ASCO 2023: Early Non Small Cell Lung Cancer

ASCO 2023: Early Non Small Cell Lung Cancer

Highlights from ASCO 2023 – eNSCLC

Aug 04, 2023

RETURN TO Highlights from ASCO 2023 – eNSCLC

MORE FROM ASCO 2023: Early Non Small Cell Lung Cancer

KRAS Mutation Does Not Influence Atezolizumab Response in NSCLC

Jun 12, 2023

Adding Pembrolizumab to Perioperative Chemotherapy Improves Event-Free Survival in Early-Stage NSCLC

Jun 12, 2023

Adjuvant Atezolizumab Impact on Recurrence Prevention and Cost Reduction in Early PD-L1 High NSCLC

May 25, 2023

Race and Curative-Intent Treatment Linked To Mortality Outcomes in Early-Stage NSCLC

May 25, 2023

New Blood-Based RNA Platform for Early Lung Cancer Diagnosis

May 25, 2023

CtDNA as Outcome Predictor in NSCLC Undergoing Targeted Therapies: A Meta-Analysis

May 25, 2023

[adinserter block="22" template="Meeting Brief Article " check="exceptions" ignore="page-type"]

ASCO 2023: Early Non Small Cell Lung Cancer

Test Your Knowledge from ASCO on eNSCLC!

Curative-Intent Treatment Improves Survival in Early NSCLC Regardless of Race

Curative-intent therapy in patients with early non-small cell lung cancer resulted in “nearly identical survival” for Black and White individuals....

Greater Benefit of Adjuvant Chemo Noted in High-Risk Patients With eNSCLC

For early-stage non-small cell lung cancer (eNSCLC) surgical resection with possible adjuvant chemotherapy for tumors with certain high-risk features remains...

[adinserter block="23" template="Article Pages" check="exceptions" ignore="page-type"]

ASCO 2023: Early Non Small Cell Lung Cancer

Highlights from ASCO 2023 – eNSCLC

MORE FROM ASCO 2023: Early Non Small Cell Lung Cancer

KRAS Mutation Does Not Influence Atezolizumab Response in NSCLC

Adding Pembrolizumab to Perioperative Chemotherapy Improves Event-Free Survival in Early-Stage NSCLC

Adjuvant Atezolizumab Impact on Recurrence Prevention and Cost Reduction in Early PD-L1 High NSCLC

Race and Curative-Intent Treatment Linked To Mortality Outcomes in Early-Stage NSCLC

New Blood-Based RNA Platform for Early Lung Cancer Diagnosis

CtDNA as Outcome Predictor in NSCLC Undergoing Targeted Therapies: A Meta-Analysis

ASCO 2023: Early Non Small Cell Lung Cancer

Test Your Knowledge from ASCO on eNSCLC!

Curative-Intent Treatment Improves Survival in Early NSCLC Regardless of Race

Greater Benefit of Adjuvant Chemo Noted in High-Risk Patients With eNSCLC

PW PODCAST

Embracing Whole-Person Health for Physician & Patient Wellness

Pre-Nups for Physicians, ACC 2024 Late-Breakers

Thriving in Medicine- Mastering Leadership and Balance

Follow Us

ASCO 2023: Early Non Small Cell Lung Cancer

Highlights from ASCO 2023 – eNSCLC

Author

MORE FROM ASCO 2023: Early Non Small Cell Lung Cancer

ASCO 2023: Early Non Small Cell Lung Cancer

PW PODCAST

Stay connected to the latest news with Physician’s Weekly